J&J, following in Sanofi's footsteps, tasks i2o with oral delivery of large molecules

Big Pharma’s embrace of i2o Therapeutics continues. After signing up Sanofi last year, the spinout from Harvard University has started 2022 by disclosing a deal to work with Johnson & Johnson on oral delivery of macromolecules.